Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226697 | 0.88 | DRD2 (0.35) | DRD2AKT1RORCDPP8DPP9 | |
| SCHEMBL10167155 | 0.85 | AKT1 (0.40) | DRD2AKT1RORCAKT2 | |
| SCHEMBL12583791 | 0.85 | DRD2 (0.38) | DRD2AKT1RORCAKT2 | |
| SCHEMBL10226580 | 0.84 | DRD2 (0.33) | DRD2AKT1 | |
| SCHEMBL10167174 | 0.83 | NPC1 (0.43) | DRD2AKT1RORCGAAAKT2 | |
| SCHEMBL15401802 | 0.83 | NPC1 (0.43) | DRD2AKT1RORCGAAAKT2 | |
| SCHEMBL15401804 | 0.83 | NPC1 (0.43) | DRD2AKT1RORCGAAAKT2 | |
| SCHEMBL13152804 | 0.80 | PGR (0.39) | DRD2 | |
| SCHEMBL538971 | 0.80 | PGR (0.39) | DRD2 | |
| SCHEMBL15276604 | 0.78 | AAK1 (0.47) | DRD2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691825-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077810-A1 | Inhibitors Of AKT Activity | PIK3CA, PIK3CD, PIK3CB | DRD2 4382/4885AKT1 11/4885RORC 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.